The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Treatment options for patients with CLL who progress after BTK inhibitor therapy
In this video, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, University of Leeds, Leeds, UK, discusses treatment options for patients that fail to respond after Bruton’s tyrosine kinase (BTK) inhibitor therapy. Dr Hillmen explains that these patients fall into two categories and receive treatment options based on which category they fall into: those who stop for intolerance or those who stop for progression. Dr Hillmen then explains the alternative options for these patients, including switching to venetoclax-based therapy, and comments on the promising results seen from Phase II trials with reversible BTK inhibitors. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
